13
Apr
The U.S. Food and Drug Administration (FDA) is continuing its effort to provide industries with updated guidance for digital health technologies. On April 3, 2023, the FDA released draft guidance titled “Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions,” requesting comments from stakeholders within 90 days of publication. This draft guidance follows a final guidance issued March 30, 2023, addressing the Section 3305 of the Consolidated Appropriations Act, 2023 amendment...